A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

A. Younes, J. M. Vose, A. D. Zelenetz, M. R. Smith, H. A. Burris, S. M. Ansell, J. Klein, W. Halpern, R. Miceli, E. Kumm, N. L. Fox, M. S. Czuczman

Research output: Contribution to journalArticlepeer-review

107 Scopus citations


Background: We conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL).Methods:Forty patients with relapsed or refractory NHL were treated with either 3 or 10 mg kg 1 mapatumumab every 21 days. In the absence of disease progression or prohibitive toxicity, patients received a maximum of six doses. Results: Mapatumumab was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity. Three patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial response. Immunohistochemistry staining of the TRAIL-R1 suggested that strong staining in tumour specimens did not appear to be a requirement for mapatumumab activity in FL. Conclusions: Mapatumumab is safe and has promising clinical activity in patients with FL.

Original languageEnglish (US)
Pages (from-to)1783-1787
Number of pages5
JournalBritish journal of cancer
Issue number12
StatePublished - Dec 7 2010


  • Apo2L
  • apoptosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this